EUCTR2016-003993-42-ES进行中（未招募）1 期
A multi-centre, randomised, double-blind, placebo-controlled trial to investigate the efficacy and safety of two concentrations of PKB171 against placebo in couples with asthenozoospermia who wish to conceive.
Prokrea BCN S.L.0 个研究点目标入组 72 人开始时间: 2017年1月4日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion criteria for the couple (i. e. must be fulfilled by male and female):
- •1.Unable to conceive for at least 12 months, despite regular and adequate unprotected sexual intercourse.
- •2.Willing and able to comply with the protocol.
- •Inclusion criteria for male subjects:
- •3.Male subjects aged 18-50 years.
- •4.Two semen analyses (at VS2 and VS3), both with the following results:
- •a.Total number of spermatozoa at least 12 000 000 per ejaculation.
- •b.Progressive motility less than 32%.
- •c.Total (progressive and non-progressive) motility less than 40%.
- •d.Normal forms at least 4%.
- •e.Viable spermatozoa at least 45%.
- •Inclusion criteria for female subjects:
- •5.Female subjects aged 18-35 years.
- •6.Body mass index (BMI) = 18 and = 30 kg/m².
- •7.Regular spontaneous menstrual cycles between 21 and 35 days in length (intercycle variations not more than ±5 days) within the last six cycles before visit VS1.
- •8.Presence of both ovaries.
- •9.Normal uterine cavity as assessed by transvaginal sonography at VS2. No submucosal fibroids or intramural fibroids exceeding 4 cm in diameter.
- •10.Normal findings at hysterosalpingography. If results from within the last 24 months are available, the examination will not be repeated at VS2.
- •11.Hormone blood test at VS2 with the following results:
- •a.Serum follicle-stimulating hormone (FSH) concentration = 12 IU/L.
- •b.LH concentration = 7 IU/L.
- •c.Estradiol (E2) concentration 25-75 pg/mL.
- •d.Prolactin < 24 ng/mL.
- •e.Progesterone (P4) < 1.5 ng/mL.
- •f.Anti-Müllerian hormone (AMH) 2.0-6.8 ng/mL
- •12.Antral follicle count (sum of both ovaries) = 7 and = 20 measured at VS2.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 72
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion criteria for the couple (i. e. must not be fulfilled by any part of the couple):
- •1.Any sexual intercourse with another partner (other than corresponding trial subject) within 12 weeks before VS1 and willing to continue until VT3.
- •2.Couples who had more than two unsuccessful previous assisted reproductive technology (ART) cycles (in vitro fertilisation, IVF, or intracytoplasmic sperm injection, ICSI) before inclusion into the trial, where unsuccessful is defined as no embryo transfer or no pregnancy was achieved. Former ART cycles, which resulted in live birth do not count.
- •3.Hypersensitivity or intolerance to pentoxifylline, xanthine derivatives or any of the excipients of the IMP.
- •4.Heavy consumer of stimulating drinks (more than five cups of coffee, tea, chocolate or cola drinks per day, or more than one can [250 mL] of energy drink per day). Daily consumption of more than 24 g alcohol per day. Smoker with more than five cigarettes per day, including portions of smokeless tobacco, nicotine patches and electronic cigarettes.
- •5.Any active substance abuse of drugs, medications or alcohol within the last five years.
- •6.Prohibited concomitant therapies within 28 days before visit VS1 until last treatment visit:
- •a.Any preparations with sex hormones or modulators of the genital system.
- •b.Selective estrogen receptor modulators (SERMs), such as tamoxifen or clomifene.
- •c.Aromatase inhibitors.
- •d.Oral pentoxifylline.
- •e.Non-medical practitioners consultations in regards to fertility.
- •7.Change in intake regimen of the following therapies within 14 days before visit VS1 until last treatment visit:
- •a.Herbal supplements, such as ginseng, maca or yohimbe.
- •b.Dietary supplements, such as vitamines, selenium, zinc, carnitine, folic acid or coenzyme Q.
- •8.Infection with human immunodeficiency virus (HIV), hepatitis B or C, genital herpes, chlamydia, gonorrhoea or syphilis.
- •9.History of malignant disease (cancer). Previous or planned chemotherapy or radiotherapy.
- •10.History of cerebral or retinal haemorrhage, acute myocardial infarction, severe cardiac arrhythmia or severe hepatic impairment.
- •11.Family history of genetic risk factors concerning pregnancy or birth. Known abnormal karyotype.
- •12.Any other condition of the subject that in the opinion of the investigator may compromise evaluation of the trial treatment or may jeopardise subject’s safety, compliance or adherence to protocol requirements.
- •13.Previous enrolment in this trial, or participation in any other clinical trial within the past 30 days prior to enrolment.
- •14.Employees of the investigator or trial centre, with direct involvement in the proposed trial or other studies under the direction of that investigator or trial centre, as well as family members of the employees or the principal investigator.
- •15.Persons committed to an institution by virtue of an order issued either by the judicial or other authorities.
- •Exclusion criteria for males:
- •16.Varicocele, as confirmed by physical and ultrasound examination. If varicocele is not suspected or results from within the last 12 months are available, the examination will not be performed at VS2.
- •Exclusion criteria for females:
- •17.History of anovulation. History of or known current poly-cystic ovary syndrome (PCOS), endometriosis type III or IV according to the American Society for Reproductive Medicine (ASRM) criteria, or fallopian tube obstruction.
- •18.Previous gynaecological surgery. One Caesarian section more than
研究者
相似试验
进行中（未招募）
不适用
A multi-centre, randomised, double-blind, placebo-controlled, dose escalation trial on safety and efficacy of activated recombinant factor VII (rFVIIa/NovoSeven®) in the treatment of post-operative bleeding in patients following cardiac surgery requiring cardiopulmonary bypassheart disease/cardiac surgeryMedDRA version: 6.1Level: PTClassification code 10061026EUCTR2004-000100-40-GBovo Nordisk A/S5,000
进行中（未招募）
不适用
A study to test the effectiveness and safety of GSK2586184 – a new oral medicine for chronic plaque psoriasis.chronic plaque psoriasisMedDRA version: 17.0Level: LLTClassification code 10050577Term: Psoriatic plaqueSystem Organ Class: 100000004858EUCTR2012-002917-20-DEGlaxoSmithKline Research & Development Ltd64
进行中（未招募）
不适用
A multi-centre, randomised, double-blind, placebo-controlled escalating dose ranging phase II study on the efficacy of DEBIO-025 to reduce HCV viral load in combination with PEGASYS 180 g/week in treatment na ve patients with chronic hepatitis C and on the safety of this combination therapy - NDtreatment na ve patients with chronic hepatitis CMedDRA version: 8.1Level: LLTClassification code 10019744Term: Hepatitis CEUCTR2006-002695-17-ITDEBIOPHARM S.A.90
进行中（未招募）
不适用
A multi-centre, randomised, double-blind, placebo-controlled, dose escalation trial on safety and efficacy of activated recombinant factor VII (rFVIIa/NovoSeven®) in the treatment of post-operative bleeding in patients following cardiac surgery requiring cardiopulmonary bypassheart disease/cardiac surgeryMedDRA version: 7.0Level: PTClassification code 10061026EUCTR2004-000100-40-DKovo Nordisk A/S5,000
进行中（未招募）
不适用
A multi-centre, randomised, double-blind, placebo-controlled, four-way incomplete crossover study to examine efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of single and repeat administration of three inhaled doses (10, 15, and 20mcg) of GSK159797 - N/AEUCTR2005-005329-68-DEGlaxoSmithKline Research & Development Limited60